Tanzania - English - Tanzania Medicinces & Medical Devices Authority

pfizer laboratories limited, kenya - medroxyprogesterone - injection - 160 mg

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

pfizer laboratories (pty) ltd - injection - see ingredients - each pre-filled syringe contains medroxyprogesterone acetate 104,0 mg

Philippines - English - FDA (Food And Drug Administration)

pfizer, inc. - medroxyprogesterone acetate - suspension for injection (sc) - 104mg/ 0.65ml

Jordan - English - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

مستودع خوري - khoury drug store - medroxyprogesterone acetate 104 mg/0.65ml - 104 mg/0.65ml

Uganda - English - National Drug Authority

pfizer laboratories (pty) - medroxyprogesterone acetate - parenteral ordinary i m pre-filled syringes - 104mg/0.65ml

Kenya - English - Pharmacy and Poisons Board

pfizer laboratories limited pfizer manufacturing belgium rijksweg 12 puurs - medroxyprogesterone acetate - suspension for injection - 104mg/0.65ml - hormonal contraceptives: progestogens for

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - medroxyprogesterone acetate, quantity: 104 mg - suspension - excipient ingredients: methyl hydroxybenzoate; propyl hydroxybenzoate; sodium chloride; macrogol 3350; polysorbate 80; monobasic sodium phosphate monohydrate; dibasic sodium phosphate dodecahydrate; methionine; povidone; sodium hydroxide; hydrochloric acid; water for injections - endometriosis,for use in the treatment of visually proven (laparoscopy) endometriosis, where the required end-point of treatment is pregnancy, or for the control of symptoms when surgery is contraindicated or has been unsuccessful.,contraception (ovulation suppression),for long-term prevention of pregnancy in women when administered at 3-month intervals.,since loss of bone mineral density (bmd) may occur in pre-menopausal women who use mpa long-term (greater than 2 years), women should be assessed, before starting treatment for contraception or endometriosis, regarding the risk of osteoporosis. women under the age of 18 years may be at risk of failing to achieve their predicted peak bmd (see section 4.4 special warnings and precautions for use).

India - English - Central Drugs Standard Control Organization

narnarayan - tab - 100/200;g

India - English - Central Drugs Standard Control Organization

shree shanker - tab - 100

India - English - Central Drugs Standard Control Organization

narnarayan - 100/200;g